Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial.

Kunadian V, Wilson N, Stocken DD, Ali H, McColl E, Burns G, Howe N, Fisher A, De Soyza A.

ERJ Open Res. 2019 Aug 5;5(3). pii: 00110-2019. doi: 10.1183/23120541.00110-2019. eCollection 2019 Jul.

2.

Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial.

Paton MF, Gierula J, Jamil HA, Lowry JE, Byrom R, Gillott RG, Chumun H, Cubbon RM, Cairns DA, Stocken DD, Kearney MT, Witte KK.

BMJ Open. 2019 Jul 17;9(7):e028613. doi: 10.1136/bmjopen-2018-028613.

3.
4.

Systematic review of endovascular intervention and surgery for common femoral artery atherosclerotic disease.

Jia X, Sun ZD, Patel JV, Flood K, Stocken DD, Scott DJA.

Br J Surg. 2019 Jan;106(1):13-22. doi: 10.1002/bjs.11026.

PMID:
30582635
5.

Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.

Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, Spicer A, Badrock J, Bernuzzi F, Cardinale V, Ainsworth HF, Heneghan MA, Thorburn D, Bathgate A, Jones R, Neuberger JM, Battezzati PM, Zuin M, Taylor-Robinson S, Donato MF, Kirby J, Mitchell-Thain R, Floreani A, Sampaziotis F, Muratori L, Alvaro D, Marzioni M, Miele L, Marra F, Giannini E, Gaudio E, Ronca V, Bonato G, Cristoferi L, Malinverno F, Gerussi A, Stocken DD, Cordell HJ, Hirschfield GM, Alexander GJ, Sandford RN, Jones DE, Invernizzi P, Mells GF; Italian PBC Study Group and the UK–PBC Consortium.

Lancet Gastroenterol Hepatol. 2018 Sep;3(9):626-634. doi: 10.1016/S2468-1253(18)30163-8. Epub 2018 Jul 13.

6.

Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.

Danilenko M, Stamp E, Stocken DD, Husain A, Zangarini M, Cranston A, Stones R, Sinclair N, Hodgson K, Bowett SA, Roblin D, Traversa S, Plummer R, Veal G, Langtry JAA, Ashworth A, Burn J, Rajan N.

JAMA Dermatol. 2018 Aug 1;154(8):913-921. doi: 10.1001/jamadermatol.2018.1610.

7.

The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility.

Wong LL, Fisher HF, Stocken DD, Rice S, Khanna A, Heneghan MA, Oo YH, Mells G, Kendrick S, Dyson JK, Jones DEJ; UK-AIH Consortium.

Hepatology. 2018 Oct;68(4):1487-1497. doi: 10.1002/hep.30031.

8.

Sustained Reduction in Severe Hypoglycemia in Adults With Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia: Two-Year Follow-up in the HypoCOMPaSS Randomized Clinical Trial.

Little SA, Speight J, Leelarathna L, Walkinshaw E, Tan HK, Bowes A, Lubina-Solomon A, Chadwick TJ, Stocken DD, Brennand C, Marshall SM, Wood R, Kerr D, Flanagan D, Heller SR, Evans ML, Shaw JAM.

Diabetes Care. 2018 Aug;41(8):1600-1607. doi: 10.2337/dc17-2682. Epub 2018 Apr 16.

PMID:
29661916
9.

Surveillance versus ablation for incidentally diagnosed small renal tumours: the SURAB feasibility RCT.

Soomro N, Lecouturier J, Stocken DD, Shen J, Hynes AM, Ainsworth HF, Breen D, Oades G, Rix D, Aitchison M.

Health Technol Assess. 2017 Dec;21(81):1-68. doi: 10.3310/hta21810.

10.

An observer-blinded randomized controlled pilot trial comparing localized immersion psoralen-ultraviolet A with localized narrowband ultraviolet B for the treatment of palmar hand eczema.

Brass D, Fouweather T, Stocken DD, Macdonald C, Wilkinson J, Lloyd J, Farr PM, Reynolds NJ, Hampton PJ.

Br J Dermatol. 2018 Jul;179(1):63-71. doi: 10.1111/bjd.16238. Epub 2018 Mar 14.

11.

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.

Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, Hacking N, Evans TRJ, Collins P, Hubner RA, Cunningham D, Primrose JN, Johnson PJ, Palmer DH.

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575. doi: 10.1016/S2468-1253(17)30156-5. Epub 2017 Jun 23. Erratum in: Lancet Gastroenterol Hepatol. 2017 Sep;2(9):e6.

12.

A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.

McPherson S, Wilkinson N, Tiniakos D, Wilkinson J, Burt AD, McColl E, Stocken DD, Steen N, Barnes J, Goudie N, Stewart S, Bury Y, Mann D, Anstee QM, Day CP.

PLoS One. 2017 Apr 18;12(4):e0175717. doi: 10.1371/journal.pone.0175717. eCollection 2017.

13.

Doxycycline: a first-line treatment for bullous pemphigoid?

Grantham HJ, Stocken DD, Reynolds NJ.

Lancet. 2017 Apr 22;389(10079):1586-1588. doi: 10.1016/S0140-6736(17)30549-4. Epub 2017 Mar 6. No abstract available.

14.

Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.

Cranston A, Stocken DD, Stamp E, Roblin D, Hamlin J, Langtry J, Plummer R, Ashworth A, Burn J, Rajan N.

Trials. 2017 Mar 7;18(1):111. doi: 10.1186/s13063-017-1812-z.

15.

A feasibility study incorporating a pilot randomised controlled trial of oral feeding plus pre-treatment gastrostomy tube versus oral feeding plus as-needed nasogastric tube feeding in patients undergoing chemoradiation for head and neck cancer (TUBE trial): study protocol.

Paleri V, Wood J, Patterson J, Stocken DD, Cole M, Vale L, Franks J, Guerrero-Urbano T, Donnelly R, Barclay S, Rapley T, Rousseau N.

Pilot Feasibility Stud. 2016 Jun 16;2:29. eCollection 2016.

16.

'Thinking that somebody's going to delay [a tonsillectomy] for one to two years is quite horrifying really': a qualitative feasibility study for the NAtional Trial of Tonsillectomy IN Adults (NATTINA Part 2).

McSweeney LA, O'Hara JT, Rousseau NS, Stocken DD, Sullivan F, Vale L, Wilkes S, Wilson JA, Haighton CA.

Clin Otolaryngol. 2017 Jun;42(3):578-583. doi: 10.1111/coa.12781. Epub 2016 Nov 10.

PMID:
27862965
17.

The NAtional randomised controlled Trial of Tonsillectomy IN Adults (NATTINA): a clinical and cost-effectiveness study: study protocol for a randomised control trial.

Rubie I, Haighton C, O'Hara J, Rousseau N, Steen N, Stocken DD, Sullivan F, Vale L, Wilkes S, Wilson J.

Trials. 2015 Jun 6;16:263. doi: 10.1186/s13063-015-0768-0.

18.

Response to comment on Little et al. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS). Diabetes Care 2014;37:2114-2122.

Little SA, Leelarathna L, Walkinshaw E, Tan HK, Chapple O, Lubina-Solomon A, Chadwick TJ, Barendse S, Stocken DD, Brennand C, Marshall SM, Wood R, Speight J, Kerr D, Flanagan D, Heller SR, Evans ML, Shaw JA.

Diabetes Care. 2014 Dec;37(12):e272-3. doi: 10.2337/dc14-1947. No abstract available.

PMID:
25414405
19.

Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS).

Little SA, Leelarathna L, Walkinshaw E, Tan HK, Chapple O, Lubina-Solomon A, Chadwick TJ, Barendse S, Stocken DD, Brennand C, Marshall SM, Wood R, Speight J, Kerr D, Flanagan D, Heller SR, Evans ML, Shaw JA.

Diabetes Care. 2014 Aug;37(8):2114-22. doi: 10.2337/dc14-0030. Epub 2014 May 22.

PMID:
24854041
20.

Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.

Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, Rawcliffe CL, Bassi C, Stocken DD, Cunningham D, O'Reilly D, Goldstein D, Robinson BA, Karapetis C, Scarfe A, Lacaine F, Sand J, Izbicki JR, Mayerle J, Dervenis C, Oláh A, Butturini G, Lind PA, Middleton MR, Anthoney A, Sumpter K, Carter R, Büchler MW.

J Clin Oncol. 2014 Feb 20;32(6):504-12. doi: 10.1200/JCO.2013.50.7657. Epub 2014 Jan 13.

PMID:
24419109
21.

Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients.

Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, Stocken DD, Rickinson AB, Steven NM, Chan AT.

Cancer Res. 2013 Mar 15;73(6):1676-88. doi: 10.1158/0008-5472.CAN-12-2448. Epub 2013 Jan 24.

22.

The value of source data verification in a cancer clinical trial.

Tudur Smith C, Stocken DD, Dunn J, Cox T, Ghaneh P, Cunningham D, Neoptolemos JP.

PLoS One. 2012;7(12):e51623. doi: 10.1371/journal.pone.0051623. Epub 2012 Dec 12.

23.

A randomised controlled trial to evaluate both the role and the optimal fractionation of radiotherapy in the conservative management of early breast cancer.

Spooner D, Stocken DD, Jordan S, Bathers S, Dunn JA, Jevons C, Dodson L, Morrison JM, Oates GD, Grieve RJ; West Midlands Oncology Breast Cancer Group.

Clin Oncol (R Coll Radiol). 2012 Dec;24(10):697-706. doi: 10.1016/j.clon.2012.08.003. Epub 2012 Oct 1.

PMID:
23036277
24.

Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test.

Wilson S, Damery S, Stocken DD, Dowswell G, Holder R, Ward ST, Redman V, Wakelam MJ, James J, Hobbs FD, Ismail T.

Br J Cancer. 2012 Apr 10;106(8):1431-8. doi: 10.1038/bjc.2012.93. Epub 2012 Mar 20.

25.

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW.

Cancer Immunol Immunother. 2011 Oct;60(10):1419-30. doi: 10.1007/s00262-011-1028-0. Epub 2011 Jun 5.

26.

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW; European Study Group for Pancreatic Cancer.

JAMA. 2010 Sep 8;304(10):1073-81. doi: 10.1001/jama.2010.1275.

PMID:
20823433
27.

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.

Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP.

J Clin Oncol. 2009 Nov 20;27(33):5513-8. doi: 10.1200/JCO.2009.24.2446. Epub 2009 Oct 26.

PMID:
19858379
28.

Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data.

Carter R, Stocken DD, Ghaneh P, Bramhall SR, Olah A, Kelemen D, Bassi C, Friess H, Dervenis C, Spry N, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer (ESPAC).

Int J Cancer. 2009 Jun 15;124(12):2960-5. doi: 10.1002/ijc.24270.

29.

Modelling prognostic factors in advanced pancreatic cancer.

Stocken DD, Hassan AB, Altman DG, Billingham LJ, Bramhall SR, Johnson PJ, Freemantle N.

Br J Cancer. 2008 Sep 16;99(6):883-93. doi: 10.1038/sj.bjc.6604568.

30.

Establishing the added benefit of measuring MMP9 in FOB positive patients as a part of the Wolverhampton colorectal cancer screening programme.

Wilson S, Taskila T, Ismail T, Stocken DD, Martin A, Redman V, Wakelam M, Perry I, Hobbs R.

BMC Cancer. 2009 Jan 28;9:36. doi: 10.1186/1471-2407-9-36.

31.

Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials.

Neoptolemos JP, Stocken DD, Tudur Smith C, Bassi C, Ghaneh P, Owen E, Moore M, Padbury R, Doi R, Smith D, Büchler MW.

Br J Cancer. 2009 Jan 27;100(2):246-50. doi: 10.1038/sj.bjc.6604838. Epub 2009 Jan 6.

32.

Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials.

Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Dervenis C, Bassi C, Büchler MW, Neoptolemos JP; Pancreatic Cancer Meta-Analysis Group.

Arch Surg. 2008 Jan;143(1):75-83; discussion 83. doi: 10.1001/archsurg.2007.17.

PMID:
18209156
33.

Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients.

Hurst NG, Stocken DD, Wilson S, Keh C, Wakelam MJ, Ismail T.

Br J Cancer. 2007 Oct 8;97(7):971-7. Epub 2007 Oct 2.

34.

A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.

Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, Buckels JA, Bramhall SR.

Ann Surg Oncol. 2007 Jul;14(7):2088-96. Epub 2007 Apr 24.

PMID:
17453298
35.

Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial.

Bassi C, Stocken DD, Olah A, Friess H, Buckels J, Hickey H, Dervenis C, Dunn JA, Deakin M, Carter R, Ghaneh P, Neoptolemos JP, Buchler MW; European Study Group for Pancreatic Cancer (ESPAC).

Dig Surg. 2005;22(5):353-63. Epub 2005 Nov 16.

PMID:
16293966
36.

Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer.

Stocken DD, Büchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Neoptolemos JP; Pancreatic Cancer Meta-analysis Group.

Br J Cancer. 2005 Apr 25;92(8):1372-81.

37.

Cationic trypsinogen mutations and pancreatitis.

Howes N, Greenhalf W, Stocken DD, Neoptolemos JP.

Clin Lab Med. 2005 Mar;25(1):39-59. Review.

PMID:
15749231
38.

Cationic trypsinogen mutations and pancreatitis.

Howes N, Greenhalf W, Stocken DD, Neoptolemos JP.

Gastroenterol Clin North Am. 2004 Dec;33(4):767-87. Review.

PMID:
15528017
39.

A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.

Hussain SA, Stocken DD, Riley P, Palmer DH, Peake DR, Geh JI, Spooner D, James ND.

Br J Cancer. 2004 Aug 31;91(5):844-9.

40.

Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.

Hussain SA, Stocken DD, Peake DR, Glaholm JG, Zarkar A, Wallace DM, James ND.

Br J Cancer. 2004 Jun 1;90(11):2106-11.

41.

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW; European Study Group for Pancreatic Cancer.

N Engl J Med. 2004 Mar 18;350(12):1200-10. Erratum in: N Engl J Med. 2004 Aug 12;351(7):726.

42.

Clinical and genetic characteristics of hereditary pancreatitis in Europe.

Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P, Truninger K, Ammann R, Cavallini G, Charnley RM, Uomo G, Delhaye M, Spicak J, Drumm B, Jansen J, Mountford R, Whitcomb DC, Neoptolemos JP; European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC).

Clin Gastroenterol Hepatol. 2004 Mar;2(3):252-61.

PMID:
15017610
43.

A phase II irinotecan-cisplatin combination in advanced pancreatic cancer.

Markham C, Stocken DD, Hassan AB.

Br J Cancer. 2003 Nov 17;89(10):1860-4.

44.
45.

Adjuvant therapy in pancreatic cancer: historical and current perspectives.

Neoptolemos JP, Cunningham D, Friess H, Bassi C, Stocken DD, Tait DM, Dunn JA, Dervenis C, Lacaine F, Hickey H, Raraty MG, Ghaneh P, Büchler MW.

Ann Oncol. 2003 May;14(5):675-92. Review.

PMID:
12702520
46.

[Adjuvant and additive therapy for cancer of the pancreas].

Neoptolemos JP, Raraty MG, Ghaneh P, Hickey H, Stocken DD, Dunn JA, Friess H, Büchler MW.

Chirurg. 2003 Mar;74(3):191-201. Review. German.

PMID:
12647075
47.

Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.

Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, Bassi C, Dervenis C, Fernandez-Cruz L, Lacaine F, Buckels J, Deakin M, Adab FA, Sutton R, Imrie C, Ihse I, Tihanyi T, Olah A, Pedrazzoli S, Spooner D, Kerr DJ, Friess H, Büchler MW; European Study Group for Pancreatic Cancer.

Ann Surg. 2001 Dec;234(6):758-68.

48.

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Büchler MW; European Study Group for Pancreatic Cancer.

Lancet. 2001 Nov 10;358(9293):1576-85.

PMID:
11716884
49.

Combined results from three phase II trials of neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus.

Archer VR, Mulholland PJ, Stocken DD, Darnton SJ, Ferry DR.

Clin Oncol (R Coll Radiol). 2001;13(3):164-9.

PMID:
11527288

Supplemental Content

Loading ...
Support Center